Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 16/20 | 0.62 |
| ▸ | GRM2 | Q14416 | 16/20 | 0.62 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481470 | 0.88 | CYSLTR1 (0.64) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL481138 | 0.88 | GRM2 (0.66) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL481488 | 0.87 | GRM2 (0.59) | CYSLTR1GRM2CYSLTR2CREBBP | |
| SCHEMBL481203 | 0.87 | GRM2 (0.63) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL481031 | 0.85 | CYSLTR1 (0.70) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL13108364 | 0.85 | CYSLTR1 (0.79) | CYSLTR1GRM2CYSLTR2 | |
| SCHEMBL481561 | 0.85 | GRM2 (0.60) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL481441 | 0.84 | CYSLTR1 (0.59) | CYSLTR1GRM2CYSLTR2MRGPRX4 | |
| SCHEMBL481287 | 0.84 | CYSLTR1 (0.59) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP | |
| SCHEMBL481341 | 0.83 | CYSLTR1 (0.59) | CYSLTR1GRM2CYSLTR2MRGPRX4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | CYSLTR1 85/4885GRM2 3/4885CYSLTR2 127/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYSLTR1 144/4885GRM2 8/4885CYSLTR2 252/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYSLTR1 144/4885GRM2 8/4885CYSLTR2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.